Drug Profile
Research programme: antibody therapeutics - F-star Therapeutics
Alternative Names: Fcab - F-star Therapeutics; Fcab antibody fragments - F-star Therapeutics; FS 101; FS 117; FS 17; FS 18; FS 20; FS 22; mAb²TMLatest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator f-star
- Developer F-star Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD223 antigen inhibitors; Checkpoint kinase inhibitors; Epidermal growth factor inhibitors; ERBB 2 receptor agonists; Hepatocyte growth factor inhibitors; OX40 receptor agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 05 Jan 2022 Merck KGaA exercises fourth licensing option from option agreement with F-star Therapeutics for antibody therapeutics
- 17 May 2021 Preclinical development is ongoing for Cancer in United Kingdom (F-star Therapeutics pipeline, May 2021)